Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 12, 2024.

Analyzing data from the H70-BCS, researchers identified around 6.2% of 70-year-olds meeting lecanemab treatment criteria, suggesting millions in Europe and the US might be eligible.

The smartphone tests accurately differentiated individuals with dementia from controls and were more sensitive to early symptoms than the Montreal Cognitive Assessment, a commonly used cognitive screening tool.

The newly cleared i-STAT TBI test can be used to help assess patients up to 24 hours after injury at patient bedside, with lab-quality results produced in 15 minutes.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on limb girdle muscular dystrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending Aprl 5, 2024.

Ram Mukunda, chief executive officer of IGC Pharma, gave context to recently announced topline data highlighting IGC-AD1 as a potential option for Alzheimer disease agitation.

The company also submitted a request for a fast track designation specific to a subcutaneous version of lecanemab and is expected to hear back within 60 days from March 2024.

Overall, the reduction of hyperactivity of delta- and gamma-band activities in mTBI suggest the treatment may reduce deafferentation and GABA-ergic inhibitory interneuron dysfunctions.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis and MS mimics.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 29, 2024.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders and multiple system atrophy.

The CLARiTI study spans across all 37 Alzheimer Disease Research Centers, collecting evidence on imaging and blood-based biomarkers to generate etiologic patient profiles of mixed dementia.

Transgender and gender-diverse patients have unique neurological considerations, but often, neurologists are unaware of the needs that are specific to this community.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 22, 2024.

A phase 2a trial demonstrated significant cognitive improvement in patients with mild cognitive impairment or mild dementia from Alzheimer or Parkinson disease through combination adrenergic activator therapy.

Over a 6-week period, patients taking IGC-AD1, on average, experienced a more significant reduction in agitation scores compared with those on placebo, with effects seen as early as week 2.

This complex waste clearance pathway within the CNS plays a crucial role in maintaining brain homeostasis, as a mechanism of protein waste removal alongside autophagy and protein aggregate ubiquitination.

Join us on April 8 on our LinkedIn and X pages for our #PreAANChat premeeting social chat ahead of the 2024 American Academy of Neurology Annual Meeting!

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Purple Day and epilepsy awareness.

Shae Datta, MD, a neurologist and headache specialist at NYU Langone Health, discussed the effects of traumatic brain injury and the need to accurately diagnose patients in a timely manner.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 15, 2024.

The FDA recently issued revised draft guidance to assist drug companies in developing treatments for early Alzheimer disease, focusing on diagnostic criteria, clinical staging, and outcome measures.

Tim Siegert, PhD, chief operating officer and co-founder of Allyx Therapeutics, provided commentary on the recently announced positive phase 1b results for ALX-001, an agent in development for Alzheimer and Parkinson disease.

Building on positive phase 1a data, ALX-001 demonstrated target engagement of mGluR5 receptor and maintained a safe profile across multiple doses.

Here's some of what is coming soon to NeurologyLive® this week.